Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion type Assertion NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_head.
- NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion description "[NAT2 slow metabolizers are more prone to the side effects of polymorphically acetylated drugs, as is the SLE-like syndrome induced by hydralazine and procainamide, the side effects due to sulphasalazine and the skin rash secondary to many sulphonamides.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_provenance.
- NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion evidence source_evidence_literature NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_provenance.
- NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion SIO_000772 18680473 NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_provenance.
- NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion wasDerivedFrom befree-20150227 NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_provenance.
- NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_assertion wasGeneratedBy ECO_0000203 NP944332.RAXy5VZdmpuZDRE4WPzhWDhkMMJiMqn_V8FcImhfLdYRE130_provenance.